Compare Gitlab Inc (GTLB) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs ResMed Inc. — how do they compare? Gitlab Inc trades at $31.47 (market cap $5.54B), while ResMed Inc. trades at $203.33 (market cap $28.80B). The key difference: ResMed Inc. is far larger — about 5.2× Gitlab Inc's market cap, and ResMed Inc. pays a 1.21% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals.
| GTLB | RMD | |
|---|---|---|
Market Cap | $5.54B | $28.80B |
Sector | Technology | Health |
52-Week High | $51.04 | $293.73 |
52-Week Low | $19.42 | $182.82 |
Enterprise Value | $4.29B | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $32.98, down 1.46% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $32.50. The company reported strong revenue growth to $759 million in 2025, though it remains unprofitable with a net margin of -2.49%. Recent news highlights its leadership in DevSecOps and AI-driven software development, including a fourth consecutive Leader recognition in Gartner's Magic Quadrant as of June 2026.
Outlook: GitLab's strategic position in the AI and DevSecOps space offers growth potential, but high valuation multiples and persistent losses pose risks. Investor sentiment is mixed, with analysts divided between buy and hold ratings. Key catalysts include execution on profitability and enterprise adoption of AI tools, while competitive pressures and macroeconomic headwinds remain concerns.
ResMed (RMD) trades at $196.37, up 1.74% with strong fundamental performance including 27.44% net margins and consistent earnings beats. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show bearish momentum despite oversold RSI conditions, while fundamentals demonstrate robust revenue growth from $5.15B to projected $5.5B in 2026.
RMD presents a compelling growth story with 40% analyst buy ratings and $245.88 consensus target suggesting 25% upside. Key risks include competitive pressures in medical technology and execution of strategic refocusing. The stock's current valuation at 19.15 P/E appears reasonable given earnings momentum and market leadership in sleep apnea treatment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
